The drug combines in a twice daily tablet Forxiga, a
SGLT2 inhibitor that reduces the reabsorption of excess glucose, and
metformin, a standard in treating the condition.
Xigduo was developed by the alliance in diabetes therapy between the
British company and Bristol-Myers Squibb, the companies said on
Wednesday. AstraZeneca will take full control of the unit later this
(Reporting by Paul Sandle; editing by
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.